ClinicalTrials.gg
Not yet recruitingNCT07243197Updated Nov 21, 2025

DragonFly M2 Pivotal Study

An interventional study of DragonFly M2 Transcatheter Mitral Valve Repair System in Mitral Valve (MV) Regurgitation, sponsored by Hangzhou Valgen Medtech Co., Ltd. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-21.

Sponsored by Hangzhou Valgen Medtech Co., Ltd · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 3 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
53
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 56 studies in Gastroesophageal Reflux with a site in China — 16 open to participants now, 17 under way, none of them phase 3. Gastroesophageal Reflux · China.

Planned enrollment
29th of 39
53 · median 90
Started
2026
with 3 others
No phase
24 of 56
11 open now
Primary completion
2026-07
later than 6 of 16 live
Registered
47th of 56
by date

Among the 56 studies in Gastroesophageal Reflux with a site in China, this one is the 29th largest by planned enrollment of the 39 interventional ones that give a count, is one of 4 that started in 2026, is one of 24 with no phase, reaches primary completion later than 6 of the 16 other live ones, and was the 47th registered.

Gastroesophageal Reflux

1,216 studies on the registry are indexed under Gastroesophageal Reflux; 204 are open to participants now.

Browse Gastroesophageal Reflux studies →

Open to participants now

16 of the 56 studies in Gastroesophageal Reflux with a site in China are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 134 Gastroesophageal Reflux studies recruiting now, 58 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies in Gastroesophageal Reflux with a site in China, or all of them as a file.
02

Study summary

To confirm the effectiveness and safety of the DragonFly M2 Transcatheter Mitral Valve Repair System for the treatment of symptomatic moderate-to-severe (3+) or severe (4+) degenerative mitral regurgitation in high surgical risk subjects.The safety and effectiveness of the first-generation device(Dragonfly Transcatheter Mitral Valve Repair System)have been previously demonstrated. This study aims to further confirm the safety and effectiveness of the new device following structural optimization based on the first-generation design.

Read the detailed description

This is a prospective, multicentric clinical investigation.

Subjects to be included in this clinical investigation suffer from symptomatic chronic moderate-to-severe (3+) or severe (4+) DMR with high or prohibitive surgical risk judged by a local investigation site's heart team .

After signing an informed consent form, subjects in the experimental group will undergo the transcatheter mitral valve repair procedure using the DragonFly M2 Transcatheter Mitral Valve Clip System. All subjects were followed up immediately after procedure, before discharge, 30 days , 6 months, 12 months after procedure, and 2, 3, 4, and 5 years after procedure.

03

Conditions studied

  • Mitral Valve (MV) Regurgitation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

1.≥ 18 years old. 2.Moderate to severe (3+) or severe (4+) chronic DMR determined by transthoracic echocardiography.

  • Transseptal catheterization is determined to be feasible by the Investigator.
  • Patients have been informed of the nature of the study, understand the purpose of the clinical trial, voluntarily participate in the study, and sign the ICF.

Exclusion criteria

Exclusion Criteria:

1)Echocardiographic evidence of intracardiac mass, thrombus, or vegetation. 2) The presence of other severe heart valve disease requiring surgical intervention.

3) Prior mitral valve leaflet surgery or transcatheter mitral valve intervention.

  • Currently participating in an drug or another device study that has not completed its primary endpoints or would clinically interfere with the endpoint of this study. Note: Trials requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational trials.
  • In the judgment of the investigator, subjects may not complete the trial according to poor compliance or in other circumstances when the investigator determines that the subject is unfit to participate in the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
53 participants (estimated)

Study arms

  • Experimental
    DragonFly M2 Transcatheter Mitral Valve Repair System

    Transcatheter mitral valve repair with the DragonFly M2 System in patients with degenerative mitral regurgitation

    Device: DragonFly M2 Transcatheter Mitral Valve Repair System

Interventions

  • DeviceDragonFly M2 Transcatheter Mitral Valve Repair System

    Edge-to-edge repair with DragonFly M2 System

06

What researchers measure

Primary outcomes

  1. Procedure success

    Procedure success: device implanted successfully, MR ≤ 2+ at discharge (or 30-day echo if unavailable), and no death or device-related reintervention within 30 days post-procedure.

    Time frame: 30 Days

Secondary outcomes

  1. Single-click release success

    successful clip detachment from the delivery system at the intended position during the first release attempt

    Time frame: Intraoperative

  2. Acute device success

    One or more Dragonfly devices are successfully delivered and released, edge-to-edge leaflet repair confirmed by echocardiogram, and successfully withdrawal of the delivery catheter.

    Time frame: Immediately after procedure

  3. surgical intervention

    surgical interventions due to post-procedural mitral valve dysfunction

    Time frame: 30 days, 6 months, and 12 months

  4. NYHA Class

    Number of patients with New York Heart Association (NYHA) Function Class I or II.

    Time frame: 30 days, 6 months, and 12 months

  5. Quality of life improvement

    Improvement in quality of life (QoL) over baseline, as measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ).

    Time frame: 30 days, 6 months, and 12 months

Other outcomes

  1. Incidence of major adverse events (MAEs)

    MAE is defined as a combined clinical endpoint of death, stroke, myocardial infarction, renal failure, and nonelective cardiovascular surgery for device or procedure-related adverse events occurring after transseptal catheterization.

    Time frame: 30 days, 6 months, and 12 months

  2. All-cause mortality

    Percentage of all-cause death includes cardiac death, non-cardiac death, and death from unknown causes.

    Time frame: 30 days, 6 months, and 12 months

  3. Cardiovascular death

    Cardiovascular death

    Time frame: 30 Days, 6 months, 12 months

07

Study locations

1 site
  • Fuwai Hospital Chinese Academy of Medical Sciences
    Shenzhen, Guangdong 518000, China
    • Xiangbin Pan, MD, PH.D · Contact+8618010155168
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2026; primary completion for Jul 2026, 6 months later.

Of 34 industry-sponsored interventional studies with no phase under Gastroesophageal Reflux, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 6 months is below that.

Counting every sponsor, half of 228 studies reached it within 32 months; a quarter within 12 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2025
First posted
Nov 21, 2025
StartEst.
Jan 15, 2026
Primary completionEst.
Jul 31, 2026
CompletionEst.
Jun 30, 2031
Last update
Nov 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07243197
Lead sponsor
Hangzhou Valgen Medtech Co., Ltd
Responsible party
Sponsor
First posted
Nov 21, 2025
Start date
Jan 15, 2026 (estimated)
Primary completion
Jul 31, 2026 (estimated)
Completion
Jun 30, 2031 (estimated)
Last update
Nov 21, 2025

Study contacts

Bo Liu
Contact
bo.liu@valgenmed.com
+86 13001980902
Xiaoxu Yang
Contact
xiaoxu.yang@valgenmed.com
+8618910330079
Xiangbin Pan
principal investigator · Chinese Academy of Medical Sciences, Fuwai Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion